Tharimmune, Inc. (THAR) saw its shares surge by 207% on Wednesday following the announcement of encouraging simulation results for its primary clinical candidate, TH104. After hours, the stock climbed an additional 42%.
Investment Strategy Insights
- Consider exploring investment tools that provide access to expert analysis and data.
What is Tharimmune?
Tharimmune is a biotechnology firm in the clinical stage, concentrating on treatments for inflammation and immune-related issues. Its leading candidate, TH104, is currently undergoing clinical trials as a potential safeguard against the effects of fentanyl and other powerful opioids.
The company employs pharmacokinetics (PK) simulations to investigate how TH104 operates within the body. Essentially, TH104 is a thin membrane in the mouth that administers nalmephene, a medication known for its effects.
In simpler terms, pharmacokinetic simulation allows researchers to predict drug behavior without the need for extensive human testing, assessing aspects such as absorption, distribution, metabolism, and excretion.
What Does the TH104 Result Mean for Users?
The latest findings indicate that TH104 can mitigate the effects of fentanyl and similar opioids, potentially taking effect within 30 minutes and providing up to 24 hours of protection. This could position TH104 as superior to existing options like naloxone, which typically lasts only 30-90 minutes.
Moreover, these results signify a promising preventive solution for military personnel and first responders who might encounter potent opioids, including weaponized fentanyl. Given the serious national security implications—due to the threat posed by these substances and the potential for widespread harm—there’s a pressing need for preemptive treatments to safeguard individuals against the rapid impacts on the nervous system caused by these drugs.
Thar Stock Performance
Over the past year, Tharimmune’s shares have fluctuated between $0.95 and $6.39. Since the beginning of the year, the stock has gained 77% in value.
However, looking back over a longer five-year span, Tharimmune’s shares have nearly plummeted by 100%.
